PREVENTION OF RELAPSES IN SYSTEMIC LUPUS-ERYTHEMATOSUS

被引:202
作者
BOOTSMA, H
SPRONK, P
DERKSEN, R
DEBOER, G
WOLTERSDICKE, H
HERMANS, J
LIMBURG, P
GMELIGMEYLING, F
KATER, L
KALLENBERG, C
机构
[1] UNIV UTRECHT HOSP, UTRECHT, NETHERLANDS
[2] LEIDEN UNIV, DEPT MED STAT, LEIDEN, NETHERLANDS
关键词
D O I
10.1016/S0140-6736(95)90114-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Many relapses of systemic lupus erythematosus (SLE) are preceded by a rise in antibodies against double-stranded DNA (anti-dsDNA). We investigated whether these relapses can be prevented by giving prednisone when a rise in anti-dsDNA occurs. 156 patients with SLE were studied. Anti-dsDNA was measured by Farr assay monthly. When a rise in anti-dsDNA was found, patients were randomly assigned either conventional treatment or 30 mg prednisone added to the current daily dose and tapering off to baseline over 18 weeks. A rise in anti-dsDNA was detected in 46 patients (24 assigned conventional treatment and 22 prednisolone). The relapse rate was higher in the conventional group than in the prednisolone group (20 vs 2, p<0 . 001). Although rises in anti-dsDNA in the prednisone group were treated with additional prednisone, the cumulative oral doses of prednisone in the two groups did not differ significantly (p=0 . 025). 7 major relapses requiring additional cytotoxic immunosuppressive treatment occurred in the conventional group Versus 2 in the prednisone group. Treatment with prednisone as soon as a significant rise in anti-dsDNA occurs prevents relapse in most cases, without increasing the cumulative dose of prednisdone given.
引用
收藏
页码:1595 / 1599
页数:5
相关论文
共 27 条
  • [1] EFFECT OF NORMALIZATION OF SERUM COMPLEMENT AND ANTI-DNA ANTIBODY ON COURSE OF LUPUS NEPHRITIS - 2 YEAR PROSPECTIVE-STUDY
    APPEL, AE
    SABLAY, LB
    GOLDEN, RA
    BARLAND, P
    GRAYZEL, AI
    BANK, N
    [J]. AMERICAN JOURNAL OF MEDICINE, 1978, 64 (02) : 274 - 283
  • [2] LONG-TERM FOLLOW-UP OF PATIENTS WITH LUPUS NEPHRITIS - A STUDY BASED ON THE CLASSIFICATION OF THE WORLD-HEALTH-ORGANIZATION
    APPEL, GB
    COHEN, DJ
    PIRANI, CL
    MELTZER, JI
    ESTES, D
    [J]. AMERICAN JOURNAL OF MEDICINE, 1987, 83 (05) : 877 - 885
  • [3] THERAPY OF LUPUS NEPHRITIS - CONTROLLED TRIAL OF PREDNISONE AND CYTOTOXIC DRUGS
    AUSTIN, HA
    KLIPPEL, JH
    BALOW, JE
    LERICHE, NGH
    STEINBERG, AD
    PLOTZ, PH
    DECKER, JL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (10) : 614 - 619
  • [4] DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS
    BOMBARDIER, C
    GLADMAN, DD
    UROWITZ, MB
    CARON, D
    CHANG, CH
    [J]. ARTHRITIS AND RHEUMATISM, 1992, 35 (06): : 630 - 640
  • [5] CONTROLLED TRIAL OF PULSE METHYLPREDNISOLONE VERSUS 2 REGIMENS OF PULSE CYCLOPHOSPHAMIDE IN SEVERE LUPUS NEPHRITIS
    BOUMPAS, DT
    AUSTIN, HA
    VAUGHN, EM
    KLIPPEL, JH
    STEINBERG, AD
    YARBORO, CH
    BALOW, JE
    [J]. LANCET, 1992, 340 (8822) : 741 - 745
  • [6] CORRELATION BETWEEN LEVELS OF DNA ANTIBODIES AND CLINICAL DISEASE ACTIVITY IN SLE - RETROSPECTIVE EVALUATION
    DAVIS, P
    PERCY, JS
    RUSSELL, AS
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1977, 36 (02) : 157 - 159
  • [7] IMMUNOSUPPRESSIVE DRUG-THERAPY IN LUPUS NEPHRITIS
    DONADIO, JV
    GLASSOCK, RJ
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1993, 21 (03) : 239 - 250
  • [8] EVALUATION OF FACTORS ASSOCIATED WITH GLUCOCORTICOID-INDUCED OSTEOPENIA IN PATIENTS WITH RHEUMATIC DISEASES
    DYKMAN, TR
    GLUCK, OS
    MURPHY, WA
    HAHN, TJ
    HAHN, BH
    [J]. ARTHRITIS AND RHEUMATISM, 1985, 28 (04): : 361 - 368
  • [9] THE TIME-DEPENDENCE OF LONG-TERM PREDICTION IN LUPUS NEPHRITIS
    ESDAILE, JM
    ABRAHAMOWICZ, M
    MACKENZIE, T
    HAYSLETT, JP
    KASHGARIAN, M
    [J]. ARTHRITIS AND RHEUMATISM, 1994, 37 (03): : 359 - 368
  • [10] THE 1ST INTERNATIONAL STANDARD FOR ANTIBODIES TO DOUBLE-STRANDED DNA
    FELTKAMP, TEW
    KIRKWOOD, TBL
    MAINI, RN
    AARDEN, LA
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1988, 47 (09) : 740 - 746